N.B.: This evaluation refers to 2018 and one for the current year is not available.

CUREVAC AG

Germany (DE)

OpenCorporation rating: 10.93 on 100

Ranking 2018: 1112 on 568 companies


Primary and secondary NACE classification:
• Research and experimental development on natural sciences and engineering (7210)
• Scientific research and development (7200)

Company description

This company, based in Germany, operates as a biopharmaceutical firm that engaged in the development of messenger RNA (mRNA) therapeutics. It was established in 2000 and has registered headquarters located in Tuebingen. It is the leading mRNA company with unique expertise and know-how for the production and therapeutic application of mRNA. It offers RNActive, which are mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases; RNArt molecular therapies that are designed to trigger the body's own production of therapeutic proteins; and RNAdjuvant RNA encoded antibodies. The company also researches and develops active ingredients for the treatment of cancer, as well as for protection against infectious diseases; and RNActive-based rabies vaccines.

[…] show more

OpenCorporation questionnaire

The read only version of the questionnaire submitted to this company is publicly available: view questionnaire.

Indicators

The rating is calculated on the following metrics (for more information visit the section Methodology).

score (max is 100)
34.8
14
1.1
0
0
0
0
95

HQ and subsidiaries

CUREVAC AG
loading subsidiaries

* The position of map pins may not reflect the exact location

Latest news about curevac ag

15 March 2020 - 12:00

Trump vuole l'esclusiva su un vaccino tedesco contro il coronavirus. È scontro con la Germania

Il presidente degli Stati Uniti sta cercando di acquisire a suon di milioni di dollari un vaccino della CureVac. Irritazione da parte del governo di Berlino.

Sul coronavirus si profila uno scontro economico e politico tra Stati Uniti e Germania. Oggetto del contendere un potenziale vaccino contro il coronavirus sul quale stanno lavorando gli scienziati tedeschi della casa biofarmaceutica CureVac.

About this evaluation

This company did not compile the OpenCorporation questionnaire, for this reason this evaluation was made only on data available to the project staff.

Claims and support from the company

If as a company manager or official of CUREVAC AG you want to enter in touch with our staff, provide more information to OpenCorporation or get an account to access and compile the company questionnaire, please write an email to support@opencorporation.org.

Tell the OpenCorporation team

If you detect corporate behavior in contrast with what emerges from the OpenCorporation corporate rating card in your country, or in the branch where you work, report it to info@opencorporation.org so that our team can take it in account.

More evaluations

This is the only evaluation available for Curevac ag.

Permament links

The link below will always open the 2018 evaluation:

2018: https://www.opencorporation.org/en/ranking/curevac-ag/2018    url copied

The link below will always open the latest evaluation available:

Last: https://www.opencorporation.org/en/ranking/curevac-ag/last    url copied